Camillia HartvigAlexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region.
She will lead the commercial activities of the regional function from Alexion’s EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.
Regarding her new role, Hartvig said: “I am delighted to join the great team in this region, that is a strategic pillar for Alexion accounting for more than a third of Alexion’s global business, and look forward to stewarding the company’s growth and development hire in the years ahead.”
Hartvig, who has more than 20 years’ experience in the pharmaceutical industry, has worked in a broad spectrum of companies, including AstraZeneca, Novartis and Allergan.
Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology.
She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.
With a first to market advantage, Ferring’s Rebyota has seen early positive adoption from gastroenterologists and infectious disease specialist in the first month post-launch. As part of their Launch Dynamix™: C.diff service, Spherix reports, while new monthly initiations are modest, a majority of physicians trialing Rebyota report high satisfaction.
Global biopharmaceutical firm UCB has entered an early drug discovery collaboration with Aitia. The collaboration is aimed at discovering and validating new drug targets and drug candidates that are linked to clinical endpoints causally in Huntington’s disease, a debilitating genetic disorder.
Foundry Innovation & Research 1—known by its much catchier acronym, FIRE1—announced Wednesday the close of a $25 million financing round. It was led by a pair of new investors in the company: Andera Partners and Novo Holdings, the holding and investment company that serves as the controlling shareholder for Novo Nordisk and Novozymes.